ophthalmic instruments, drugs and consumables,
including Zeiss, Alcon, STAAR, Novartis, and Bausch
& Lomb Trading Company. “They can supply the
world-class ophthalmic products and technology in
China. Through close strategic collaboration with
them, we can offer the latest and best treatments
for Chinese patients,” Li explains. “As the industry
evolves, we are seeing the introduction of cutting-
edge technologies like AI and genetic technology, and
it’s evident they will only continue to play a bigger
role in our future.”
To deliver the best possible outcomes for its
patients, Li explains that AIER only partners with
organisations that have the most advanced and
innovative technologies in their respective fields of
ophthalmology. Zeiss has its VisuMax ‘SMILE’ Lasik
surgery system to correct near-sightedness, Alcon has
the LenSx femtosecond cataract surgery system, and
STAAR uses the ICL lens to treat refractive errors,”
he notes. “Novartis last year launched its Lucentis
drug to treat visual impairment, and Bausch & Lomb
has the Stellaris PC platform, which provides the
most advanced technology for both vitreoretinal and
cataract surgery in a single system.”LOOKING AHEAD
Under China’s current vision health policy
environment, it is expected that by 2020, the number
of myopic patients (those with near-sightedness)
in the country will increase to 704–711 million –
double that of the entire population of the US.
Over the years, AIER has solved vision problems
for more than 1.5 million of these patients through
myopia surgery. Since the arrival of the SCHWIND
AMARIS laser system in China in 2011, more than“It is our pleasure to work with AIER for the past 15 years, and we are
glad to see the changes and developments in the ophthalmic market of
China. AIER has not slowed down, it now extends to Europe and is our
key customer there too.” – Kave Ku, Surgical Director, Greater China,
Korea and India, Bausch + Lomb
Half page advert
BAUSCH & LOMB